Journal: Drug Delivery

Article Title: Formulation and in vivo assessment of terconazole-loaded polymeric mixed micelles enriched with Cremophor EL as dual functioning mediator for augmenting physical stability and skin delivery

doi: 10.1080/10717544.2018.1436098

Figure Lengend Snippet: 3-D plot model graphs demonstrating the effect of factors; X 1 : weight ratio of total Pluronics to drug, X 2 : weight ratio of Pluronic P123 to Pluronic F127, and X 3 : percent of Cremophor EL in aqueous medium on micellar incorporation efficiency percent (MIE%) (a and b) and mean micellar size (c and d).

Article Snippet: Pluronic F127, Pluronic P123, and Cremophor EL were purchased from BASF Co. (Florham Park, NJ).

Techniques:

Journal: Drug Delivery

Article Title: Formulation and in vivo assessment of terconazole-loaded polymeric mixed micelles enriched with Cremophor EL as dual functioning mediator for augmenting physical stability and skin delivery

doi: 10.1080/10717544.2018.1436098

Figure Lengend Snippet: (a) Cumulative amount of TCZ permeated per unit area across skin via optimal PMMs formulation (F7) compared to PMMs lacking Cremophor EL and TCZ suspension. (b) Cumulative amount of TCZ deposited per unit area in the skin via optimal PMMs formulation (F7) compared to TCZ suspension.

Article Snippet: Pluronic F127, Pluronic P123, and Cremophor EL were purchased from BASF Co. (Florham Park, NJ).

Techniques:

Journal: British Journal of Pharmacology

Article Title: New positron emission tomography tracer [11C]carvedilol reveals P-glycoprotein modulation kinetics

doi: 10.1038/sj.bjp.0706283

Figure Lengend Snippet: Distribution volume (DV) of [ 11 C]carvedilol in the brain at 0, 10,15, 25, and 50 mg kg −1 cyclosporin A. The bars represent mean DV±s.e.m. ( n =3–5). The fitted curve is mathematically described as a four-parameter Hill plot:

Article Snippet: Medetomidine (Domitor®, 1 mg medetomidine HCl ml−1 ) from Pfizer Animal Health B.V. (Capelle a/d IJssel, the Netherlands), CsA (50 mg ml−1 ) in cremophore EL (650 mg ml−1 ) (Sandimmune®) from Novartis (Basel, Switzerland), and MK 571 from Alexis Corp. (Lausen, Switzerland).

Techniques:

Journal: British Journal of Pharmacology

Article Title: New positron emission tomography tracer [11C]carvedilol reveals P-glycoprotein modulation kinetics

doi: 10.1038/sj.bjp.0706283

Figure Lengend Snippet: Plasma clearance of [ 11 C]carvedilol in the presence of several dosages cyclosporin A. Each point represents the mean±s.e.m.

Article Snippet: Medetomidine (Domitor®, 1 mg medetomidine HCl ml−1 ) from Pfizer Animal Health B.V. (Capelle a/d IJssel, the Netherlands), CsA (50 mg ml−1 ) in cremophore EL (650 mg ml−1 ) (Sandimmune®) from Novartis (Basel, Switzerland), and MK 571 from Alexis Corp. (Lausen, Switzerland).

Techniques:

Journal: British Journal of Pharmacology

Article Title: New positron emission tomography tracer [11C]carvedilol reveals P-glycoprotein modulation kinetics

doi: 10.1038/sj.bjp.0706283

Figure Lengend Snippet: Time–activity curves of [ 11 C]carvedilol in the brain with several dosages cyclosporin A, measured by PET. Each point represents mean±s.e.m.

Article Snippet: Medetomidine (Domitor®, 1 mg medetomidine HCl ml−1 ) from Pfizer Animal Health B.V. (Capelle a/d IJssel, the Netherlands), CsA (50 mg ml−1 ) in cremophore EL (650 mg ml−1 ) (Sandimmune®) from Novartis (Basel, Switzerland), and MK 571 from Alexis Corp. (Lausen, Switzerland).

Techniques: Activity Assay, Positron Emission Tomography

Journal: Pharmaceutics

Article Title: A Repurposed Drug for Brain Cancer: Enhanced Atovaquone Amorphous Solid Dispersion by Combining a Spontaneously Emulsifying Component with a Polymer Carrier

doi: 10.3390/pharmaceutics10020060

Figure Lengend Snippet: Gibbs free energy of mixing (ΔGmix) diagrams of atovaquone in polymer carriers with the SEC from formulation 4 present. ( a ) Atovaquone and PVP K30. ( b ) Atovaquone and Kollidon VA64. ( c ) Atovaquone and Affinisol 15LV.

Article Snippet: Kollidon VA64, Kollidon 30, and Cremophor RH 40 were kindly donated from BASF Corp. (Florham Park, NJ, USA).

Techniques: Size-exclusion Chromatography

Journal: Drug Delivery

Article Title: Formulation and in vivo assessment of terconazole-loaded polymeric mixed micelles enriched with Cremophor EL as dual functioning mediator for augmenting physical stability and skin delivery

doi: 10.1080/10717544.2018.1436098

Figure Lengend Snippet: 3-D plot model graphs demonstrating the effect of factors; X 1 : weight ratio of total Pluronics to drug, X 2 : weight ratio of Pluronic P123 to Pluronic F127, and X 3 : percent of Cremophor EL in aqueous medium on micellar incorporation efficiency percent (MIE%) (a and b) and mean micellar size (c and d).

Article Snippet: Pluronic F127, Pluronic P123, and Cremophor EL were purchased from BASF Co. (Florham Park, NJ).

Techniques:

Journal: Pain Research & Management

Article Title: Evoked and Ongoing Pain-Like Behaviours in a Rat Model of Paclitaxel-Induced Peripheral Neuropathy

doi: 10.1155/2018/8217613

Figure Lengend Snippet: Effect of paclitaxel administration on heat hypersensitivity. Graph shows the mean ± SEM of the hind paw withdrawal latency to a radiant heat stimulus. BL = baseline before paclitaxel/vehicle administration. Arrows indicate four injections of 2 mg/kg paclitaxel or equivalent volume of vehicle on days 0, 2, 4, and 6 ( n =6 per group).

Article Snippet: When using paclitaxel from Actavis, the vehicle stock was supplemented with 2 mg/mL sodium citrate (Sigma, UK).

Techniques:

Journal: Pain Research & Management

Article Title: Evoked and Ongoing Pain-Like Behaviours in a Rat Model of Paclitaxel-Induced Peripheral Neuropathy

doi: 10.1155/2018/8217613

Figure Lengend Snippet: Effect of paclitaxel administration on motor coordination. Graph shows the mean ± SEM of the latency to fall from an accelerating RotaRod apparatus. BL = baseline before paclitaxel/vehicle administration. Arrows indicate four injections of 2 mg/kg paclitaxel or equivalent volume of vehicle on days 0, 2, 4, and 6 ( n =6 per group).

Article Snippet: When using paclitaxel from Actavis, the vehicle stock was supplemented with 2 mg/mL sodium citrate (Sigma, UK).

Techniques:

Journal: Pain Research & Management

Article Title: Evoked and Ongoing Pain-Like Behaviours in a Rat Model of Paclitaxel-Induced Peripheral Neuropathy

doi: 10.1155/2018/8217613

Figure Lengend Snippet: Time course of paclitaxel-induced mechanical hypersensitivity. Graphs show the mean ± SEM of the number of withdrawal responses to (a) von Frey 4 g, (b) von Frey 8 g, and (c) von Frey 15 g, respectively. Arrows indicate four injections of 2 mg/kg paclitaxel or equivalent volume of vehicle on days 0, 2, 4, and 6. BL = baseline before paclitaxel/vehicle administration. Res = resolution of mechanical hypersensitivity, which occurred between days 174 and 219. ∗ p

Article Snippet: When using paclitaxel from Actavis, the vehicle stock was supplemented with 2 mg/mL sodium citrate (Sigma, UK).

Techniques:

Journal: Pain Research & Management

Article Title: Evoked and Ongoing Pain-Like Behaviours in a Rat Model of Paclitaxel-Induced Peripheral Neuropathy

doi: 10.1155/2018/8217613

Figure Lengend Snippet: Effect of paclitaxel administration on overnight spontaneous wheel-running behaviour. Graphs show the mean ± SEM of the (a) time spent on the wheel, (b) total distance travelled, (c) maximal acceleration generated, and (d) number of times the wheel was accessed by individual rats overnight (7.10 pm–6.30 am) before paclitaxel/vehicle administration (BL) and then on day 7, day 28, and day 35 following the initial injection of 2 mg/kg paclitaxel or vehicle. Arrows indicate four injections of 2 mg/kg paclitaxel or equivalent volume of vehicle on days 0, 2, 4, and 6. ∗ p

Article Snippet: When using paclitaxel from Actavis, the vehicle stock was supplemented with 2 mg/mL sodium citrate (Sigma, UK).

Techniques: Generated, Injection

Journal: Pain Research & Management

Article Title: Evoked and Ongoing Pain-Like Behaviours in a Rat Model of Paclitaxel-Induced Peripheral Neuropathy

doi: 10.1155/2018/8217613

Figure Lengend Snippet: Time course of paclitaxel-induced cold hypersensitivity. Graph shows the median ± interquartile range of the hind paw response to acetone application catergorised by the cold score. BL = baseline before paclitaxel/vehicle administration. Arrows indicate four injections of 2 mg/kg paclitaxel or equivalent volume of vehicle on days 0, 2, 4, and 6. ∗ p

Article Snippet: When using paclitaxel from Actavis, the vehicle stock was supplemented with 2 mg/mL sodium citrate (Sigma, UK).

Techniques:

Journal: Pain Research & Management

Article Title: Evoked and Ongoing Pain-Like Behaviours in a Rat Model of Paclitaxel-Induced Peripheral Neuropathy

doi: 10.1155/2018/8217613

Figure Lengend Snippet: Time course of weight gain in rats following paclitaxel or vehicle administration. Graph shows mean ± SEM of rats' weight (g) from before paclitaxel/vehicle administration (BL) up to day 174. Arrows indicate four injections of 2 mg/kg paclitaxel or equivalent volume of vehicle on days 0, 2, 4, and 6 ( n =18 per group).

Article Snippet: When using paclitaxel from Actavis, the vehicle stock was supplemented with 2 mg/mL sodium citrate (Sigma, UK).

Techniques:

Journal: Pain Research & Management

Article Title: Evoked and Ongoing Pain-Like Behaviours in a Rat Model of Paclitaxel-Induced Peripheral Neuropathy

doi: 10.1155/2018/8217613

Figure Lengend Snippet: Effect of paclitaxel administration on spontaneous burrowing behaviour. Graphs show the mean ± SEM of (a) gravel displaced from burrowing tubes and (b) latency to start burrowing by individual rats before paclitaxel/vehicle administration (BL) and then on day 7 and day 28 following the initial injection of 2 mg/kg paclitaxel or vehicle. ∗ p

Article Snippet: When using paclitaxel from Actavis, the vehicle stock was supplemented with 2 mg/mL sodium citrate (Sigma, UK).

Techniques: Injection

Journal: Neuron

Article Title: Paclitaxel reduces axonal Bclw to initiate IP3R1-dependent axon degeneration

doi: 10.1016/j.neuron.2017.09.034

Figure Lengend Snippet: The Bclw BH4 domain is sufficient to prevent paclitaxel-induced axon degeneration (A) Schematic of stabilized alpha-helix of Bcl2 domain (SAHB) peptides modeled after the BH4 domains of Bclw (PDB ID 4CIM, aa 12-31), Bcl2 (PDB ID 2XA0, aa 13-32), and Bclx L (PDB ID 4QVE, aa 6-26). (B) Percent release of ANTS/DPX encapsulated liposomes in the presence of Bax, Bim SAHB A2 , and/or Bclw BH4 SAHB A as indicated; n=3; data represent mean ± SD. (C) Axons from compartmented cultures after protein transfection with FITC-BH4 SAHB peptides of Bclw, Bcl2, or Bclx L showing FITC signal (left) and Tuj1 signal (right); scale bar = 20 µm. (D) Degeneration index of axons treated with paclitaxel or DMSO after protein transfection of FITC-BH4 SAHB-Bclw, Bcl2, or Bclx L into axons; *p

Article Snippet: Paclitaxel was prepared as 1 part 6 mg/mL paclitaxel stock solution diluted in vehicle (1:1 v/v Cremophor EL [EMD Millipore] and dehydrated ethanol) and 2 parts sterile saline and injected at 10 µL/g.

Techniques: Transfection

Journal: Neuron

Article Title: Paclitaxel reduces axonal Bclw to initiate IP3R1-dependent axon degeneration

doi: 10.1016/j.neuron.2017.09.034

Figure Lengend Snippet: Loss of Bclw exacerbates paclitaxel-induced neuropathy in vivo . (A) Thermal pain threshold measured as time to lick or withdraw hindpaw on a 50°C hot-plate. (B) Mechanical pain threshold determined from response to von Frey filaments. (C-F) Quantification and representative images of Tuj1 positive sensory fibers (green, arrowheads) entering the epidermis per 225 µm epidermal length in thick (C-D) and thin (E-F) skin, DAPI counterstain (blue); scale bar = 25 µm; *p

Article Snippet: Paclitaxel was prepared as 1 part 6 mg/mL paclitaxel stock solution diluted in vehicle (1:1 v/v Cremophor EL [EMD Millipore] and dehydrated ethanol) and 2 parts sterile saline and injected at 10 µL/g.

Techniques: In Vivo

Journal: Neuron

Article Title: Paclitaxel reduces axonal Bclw to initiate IP3R1-dependent axon degeneration

doi: 10.1016/j.neuron.2017.09.034

Figure Lengend Snippet: Paclitaxel reduces axonal Bclw mRNA and protein levels bclw (A), bcl2 (D) and bclx L (G) mRNA analyzed by qRT-PCR from cell body or axon lysate of compartmented cultures after 24 hours of paclitaxel or vehicle treatment to axons. Data normalized to gapdh ; *p

Article Snippet: Paclitaxel was prepared as 1 part 6 mg/mL paclitaxel stock solution diluted in vehicle (1:1 v/v Cremophor EL [EMD Millipore] and dehydrated ethanol) and 2 parts sterile saline and injected at 10 µL/g.

Techniques: Quantitative RT-PCR

Journal: Neuron

Article Title: Paclitaxel reduces axonal Bclw to initiate IP3R1-dependent axon degeneration

doi: 10.1016/j.neuron.2017.09.034

Figure Lengend Snippet: Paclitaxel reduces translation of Bclw via reduction of SFPQ (A) Western blot and (B) quantification of SFPQ protein from cell body or distal axon lysate of compartmented cultures after 24 hours of paclitaxel treatment to axons; data normalized to actin; *p

Article Snippet: Paclitaxel was prepared as 1 part 6 mg/mL paclitaxel stock solution diluted in vehicle (1:1 v/v Cremophor EL [EMD Millipore] and dehydrated ethanol) and 2 parts sterile saline and injected at 10 µL/g.

Techniques: Western Blot

Journal: Neuron

Article Title: Paclitaxel reduces axonal Bclw to initiate IP3R1-dependent axon degeneration

doi: 10.1016/j.neuron.2017.09.034

Figure Lengend Snippet: Axonal Bclw prevents paclitaxel-induced degeneration (A) Binarized images of Tuj1 immunostaining of axons treated with paclitaxel or vehicle after protein transfection with Bclw, Bcl2, Bclx L . (B) Degeneration index of (A) and untransfected (Untrans) control; *p

Article Snippet: Paclitaxel was prepared as 1 part 6 mg/mL paclitaxel stock solution diluted in vehicle (1:1 v/v Cremophor EL [EMD Millipore] and dehydrated ethanol) and 2 parts sterile saline and injected at 10 µL/g.

Techniques: Immunostaining, Transfection

Journal: Neuron

Article Title: Paclitaxel reduces axonal Bclw to initiate IP3R1-dependent axon degeneration

doi: 10.1016/j.neuron.2017.09.034

Figure Lengend Snippet: Paclitaxel acts locally to induce axon degeneration without cell body apoptosis (A) Tuj1 immunostaining and corresponding binarized images of axons of E15 DRG neurons grown in compartmented cultures treated with 30 nM paclitaxel or DMSO vehicle control for 24 hours to cell body (left) or distal axon (right) compartments; scale bar = 40 µm. Red boxes outline regions shown at higher magnification in the center panels. Features characteristic of degenerating axons are seen: red arrowheads indicate a “beads on a string” appearance and the red lines indicate interruptions in Tuj1 continuity. (B) Quantification of axonal degeneration: ratio of area of fragmented axons to total axon area (degeneration index); *p

Article Snippet: Paclitaxel was prepared as 1 part 6 mg/mL paclitaxel stock solution diluted in vehicle (1:1 v/v Cremophor EL [EMD Millipore] and dehydrated ethanol) and 2 parts sterile saline and injected at 10 µL/g.

Techniques: Immunostaining

Journal: PLoS ONE

Article Title: Chloroquine Enhances Gefitinib Cytotoxicity in Gefitinib-Resistant Nonsmall Cell Lung Cancer Cells

doi: 10.1371/journal.pone.0119135

Figure Lengend Snippet: Activation of apoptotic pathway by gefitinib and chloroquine in PC-9/wt and PC-9/gef ells. PC-9/wt, PC-9/gefB4 and PC-9/gefE3 cells were treated with gefitinib (100 nM) and chloroquine (CQ, 10 μM) for 24 h. Total protein of treated cells was harvested. Procaspase 3, active caspase 3, PARP cleavage levels was analyzed with Western blot assay. Each lane contained 30 μg protein for all experiments. Results were repeated in independent experiments.

Article Snippet: The primary antibodies included microtubule-associated protein 1 light chain 3 (LC3; Cell Signaling Technology, Beverly, MA, U.S.A., #2775), caspase 3 (Cell Signaling Technology, #9668), and PARP (Cell Signaling Technology, #9542), α-tubulin (Cell Signaling Technology, #2144) and β-actin antibody (Millipore, Bedford, MA, U.S.A.).

Techniques: Activation Assay, Western Blot

Journal: Drug Delivery

Article Title: Formulation and in vivo assessment of terconazole-loaded polymeric mixed micelles enriched with Cremophor EL as dual functioning mediator for augmenting physical stability and skin delivery

doi: 10.1080/10717544.2018.1436098

Figure Lengend Snippet: 3-D plot model graphs demonstrating the effect of factors; X 1 : weight ratio of total Pluronics to drug, X 2 : weight ratio of Pluronic P123 to Pluronic F127, and X 3 : percent of Cremophor EL in aqueous medium on micellar incorporation efficiency percent (MIE%) (a and b) and mean micellar size (c and d).

Article Snippet: Pluronic F127, Pluronic P123, and Cremophor EL were purchased from BASF Co. (Florham Park, NJ).

Techniques: